Lynozyfic™ (linvoseltamab) approved in the european union for the treatment of relapsed/refractory multiple myeloma

Approval of lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission tarrytown, n.y., april 28, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the european commission (ec) has granted conditional marketing approval of lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (r/r) multiple myeloma (mm).
REGN Ratings Summary
REGN Quant Ranking